Экономическая эффективность доклинической диагностики болезни Паркинсона: марковская модель

Vartanov, Sergey and Bogatova, Irina and Denisova, Irina and Kucheryanu, Valerian and Tourdyeva, Natalia and Chubarova, Tatyana and Shakleina, Marina and Polterovich, Victor (2020): Экономическая эффективность доклинической диагностики болезни Паркинсона: марковская модель. Forthcoming in: The bulletin of the Far Eastern Federal University. Economics and Management

Abstract

This work is devoted to the pharmacoeconomic analysis of the results of the introduction of early (preclinical) diagnosis of Parkinson's disease in Russia. On the basis of a combination of socio-economic determinants and a panel of blood biomarkers, it may be possible to identify among the entire population a “risk group” - people most likely to develop parkinsonism or are already sick with it at the preclinical stage. Together with the approach traditionally used in the pharmacoeconomics of chronic and long-term diseases, based on the representation of the dynamics of the development of the disease using Markov chains - discrete random processes without memory - this makes it possible to analyze the economic effects of early detection of cases and conducting preventive preclinical therapy. The work investigated the Markov model of Parkinson's disease, consisting of nine states - five states corresponding to the stages HY1-HY5, two preclinical states ("risk group", "prodromal state"). Using as the initial data for the model, the probability of transition between states and health-adjusted quality of life (HRQoL) estimates, published in a number of works of researchers affiliated with AbbVie Corporation, and calculating the cost of therapy based on open data on the cost of drugs and procedures in Russian market (eapteka, apteka.ru, piluli.ru, website of the Ministry of Health of the Russian Federation), the work shows that due to the introduction of preclinical diagnostics and preventive treatment at preclinical stages, identified patients can significantly increase the average survival time (in quality of life-adjusted years) compared to standard therapy, and the average cost per patient until the end of life can be significantly reduced.

• Item Type: MPRA Paper
• English Title: Cost-effectiveness of preclinical Parkinsonism diagnosis: a Markov model
• Language: Russian
• Keywords: Markov chain with discrete time, Markov model, Parkinson disease, pharmacoeconomics
• Subjects: C - Mathematical and Quantitative Methods > C0 - General > C02 - Mathematical Methods; C - Mathematical and Quantitative Methods > C6 - Mathematical Methods ; Programming Models ; Mathematical and Simulation Modeling > C63 - Computational Techniques ; Simulation Modeling; C - Mathematical and Quantitative Methods > C6 - Mathematical Methods ; Programming Models ; Mathematical and Simulation Modeling > C65 - Miscellaneous Mathematical Tools; I - Health, Education, and Welfare > I1 - Health > I10 - General; I - Health, Education, and Welfare > I1 - Health > I11 - Analysis of Health Care Markets; I - Health, Education, and Welfare > I1 - Health > I19 - Other

References

Рудакова А.В., Левин О.С. Фармакоэкономические аспекты комбинированной терапии развернутой стадии болезни Паркинсона. Нервные болезни, № 2, 2017, 30-34. Lowin J. et al. The cost-effectiveness of levodopa/carbidopa intestinal gel compared to standard care in advanced Parkinson’s disease // Journal of medical economics. 2017, Vol. 20, №. 11. P. 1207-1215. Munoz D. A., M. S. Kilinc, H. B. Nembhard, C. Tucker, and X. Huang. Evaluating the Cost-Effectiveness of an Early Detection of Parkinson’s Disease through Innovative Technology The Engineering Economist, 2017, vol. 62, issue 2, 180-196. Siderowf A., B. Ravina, H. A. Glick. Preference-based quality-of-life in patients with Parkinson's disease. Neurology. 59(1):103-108, 2002. Sonnenberg FA, Beck JR: Markov models in medical decision making: a practical guide // Medical Decision Making, Philadelphia, 1993, 13:322-338 Куликов А. Ю., Нгуен Т. Т., Тихомирова А. В. Методология моделирования в фармакоэкономике // Фармакоэкономика. Современная фармакоэкономика и фармакоэпидемиология. 2011. №4. Palmer A.J. et al. The CORE Diabetes Model: Projecting longterm clinical outcomes, costs and cost-effectiveness of interventions in diabetes mellitus (types 1 and 2) to support clinical and reimbursement decision-making // Curr. Med. Res. Opin. – 2004. Дедов И.И. и др. Фармакоэкономическое моделирование отдаленных результатов лечения сахарного диабета 2 типа у пациентов, получавших современные аналоги инсулина по сравнению с терапией пероральными сахароснижающими препаратами // Сахарный диабет. 2010. №1. Brookmeyer R. et al. Forecasting the prevalence of preclinical and clinical Alzheimer's disease in the United States //Alzheimer's & Dementia. – 2018. – Т. 14. – №. 2. Davey et al. "Cost‐Effectiveness of Pergolide Compared to Bromocriptine in the Treatment of Parkinson's Disease: A Decision‐Analytic Model." Value in Health 4.4 (2001): 308-315 Рудакова А.В., Левин О.С. Фармакоэкономические аспекты комбинированной терапии развернутой стадии болезни Паркинсона // Нервные болезни. 2017. №2. Johnson S. J. et al. An economic model of Parkinson's disease: Implications for slowing progression in the United States //Movement Disorders. – 2013. – Т. 28. – №. 3. – С. 319-326. Sonnenberg F. A., Beck J. R. Markov models in medical decision making: a practical guide //Medical decision making. – 1993. – Т. 13. – №. 4. – С. 322-338. Lowin J. et al. A cost-effectiveness analysis of levodopa/carbidopa intestinal gel compared to standard care in late stage Parkinson’s disease in the UK // Journal of medical economics. – 2011. – Т. 14. – №. 5. – С. 584-593. Протокол ведения больных. Болезнь Паркинсона // Проблемы стандартизации в здравоохранении 2005; 3: 74–166. Шаклеина М.В., Богатова И.Э., Вартанов С.А., Денисова И.А., Турдыева Н.А., Чубарова Т.В., Полтерович В.М. Социально-экономические детерминанты болезни Паркинсона для развитых и развивающихся стран // Экономика и математические методы (подана) Угрюмов М. В. Разработка доклинической диагностики и превентивного лечения нейродегенеративных заболеваний // Журнал неврологии и психиатрии им. СС Корсакова. – 2015. – Т. 115. – №. 11. – С. 4-14. Хакимова, Г. Р., Дегтярёва, Е. А., Козина, Е. А., Кучеряну, В. Г., Угрюмов, М. В. "Провокационный тест" как новый подход к ранней диагностике болезни Паркинсона // Доклады Академии наук. – Федеральное государственное бюджетное учреждение" Российская академия наук", 2015. – Т. 460. – №. 6. – С. 733-735. Ким А. Р., Угрюмов М. В. Изменение концентрации катехоламинов в крови в условиях экспериментальных моделей болезни паркинсона как биомаркёр ранней стадии заболевания // Доклады Академии наук. – Федеральное государственное бюджетное учреждение "Российская академия наук", 2015. – Т. 464. – №. 4. – С. 494-497.